The FDA has approved a new first-line maintenance therapy for extensive-stage small-cell lung cancer, combining Jazz Pharmaceuticals' Zepzelca (lurbinectedin) with Roche's Tecentriq (atezolizumab). This marks the first combination therapy approved for this indication. Approval stemmed from the phase III Imforte study, which demonstrated a 46% reduction in disease progression risk and a 27% reduction in death risk relative to Tecentriq alone. The approval was granted ahead of the scheduled Oct. 7 PDUFA date, spotlighting key progress in lung cancer treatment. In addition, FDA cleared a new generic version of the abortion pill mifepristone from Evita Solutions LLC, underscoring evolving options in reproductive health therapeutics.